KRAS and colorectal carcinoma: The expression of KRAS and p53 genes are mostly related to the pathological characteristics and treatment response of CRC patients, and therefore, are widely used to predict the outcomes of CRC treatments (Al‐Kuraya, 2009; Chaar et al., 2014; Ross, 2012).